Stockscreener 앱 받기
33.70
0.99%
0.33
시간 외 거래:
33.80
0.10
+0.30%
전일 마감가:
$33.37
열려 있는:
$34
하루 거래량:
976.03K
Relative Volume:
1.29
시가총액:
$2.13B
수익:
-
순이익/손실:
$-107.85M
주가수익비율:
-15.25
EPS:
-2.21
순현금흐름:
$-106.82M
1주 성능:
-2.57%
1개월 성능:
-20.89%
6개월 성능:
-2.74%
1년 성능:
+125.72%
1일 변동 폭
$33.34
$34.35
1주일 범위
$32.25
$36.28
52주 변동 폭
$15.37
$51.61
베라 테라 Stock (VERA) Company Profile
명칭
Vera Therapeutics Inc
전화
650-770-0077
주소
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
VERA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
33.70 | 2.13B | 0 | -107.85M | -106.82M | -2.21 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
베라 테라 Stock (VERA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-21 | 개시 | Wells Fargo | Overweight |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-01-25 | 개시 | Oppenheimer | Outperform |
| 2024-01-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-12-18 | 개시 | Raymond James | Outperform |
| 2023-11-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-08-16 | 개시 | Guggenheim | Buy |
| 2023-01-04 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-01-04 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-07-12 | 개시 | JP Morgan | Overweight |
| 2022-05-02 | 개시 | H.C. Wainwright | Buy |
| 2022-04-19 | 개시 | Wedbush | Outperform |
모두보기
베라 테라 주식(VERA)의 최신 뉴스
Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Average Rating of “Buy” from Analysts - Defense World
Possible Bearish Signals With Vera Therapeutics Insiders Disposing Stock - Simply Wall St
Vera Therapeutics Releases Updated Corporate Presentation Following J.P. Morgan Healthcare Conference - Defense World
When the Price of (VERA) Talks, People Listen - Stock Traders Daily
JPMorgan Chase & Co. Decreases Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Nephrotic Syndrome Market Set to Grow Substantially Through 2034, DelveInsight Projects | GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squib - The Globe and Mail
Vera Therapeutics Getting Closer To Key Technical Benchmark - MSN
Head to Head Comparison: CannTrust (OTCMKTS:CNTTF) versus Vera Therapeutics (NASDAQ:VERA) - Defense World
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Vera Therapeutics Awards New Employee Stock Options and RSUs Worth $42.19 Per Share - StockTitan
Vera Therapeutics Stocks Surge Amid Strategic Moves - TipRanks
Vera Therapeutics (NASDAQ:VERA) Shares Gap Down Following Insider Selling - Defense World
What's Going On With Vera Therapeutics Stock?Vera Therapeutics (NASDAQ:VERA) - Benzinga
Vera Therapeutics (NASDAQ:VERA) Shares Gap Down After Insider Selling - MarketBeat
Vera Therapeutics Highlights Atacicept Progress at Conference - TipRanks
Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor - GlobeNewswire
Vera Therapeutics Secures Stanford's Novel B Cell Therapy VT-109 in Exclusive Deal - StockTitan
Vera Therapeutics CEO Marshall sells shares for $730,535 By Investing.com - Investing.com Australia
Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce Sells 17,500 Shares - MarketBeat
Vera Therapeutics (NASDAQ:VERA) Trading Down 7.3%Should You Sell? - MarketBeat
Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
How to Take Advantage of moves in (VERA) - Stock Traders Daily
Is Vera Therapeutics The NEXT BIG THING? Stock Price Soars! - Truth or Fiction
Vera Therapeutics to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Franklin Resources Inc. Sells 5,859 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Certain Options of Vera Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-DEC-2024. - Marketscreener.com
Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Rating of "Buy" by Brokerages - MarketBeat
Geode Capital Management LLC Buys 20,223 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics, Inc. (NASDAQ:VERA) Position Boosted by Geode Capital Management LLC - MarketBeat
Barclays PLC Acquires 41,394 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - MarketBeat
Vera Therapeutics: Strong Data In IgAN, But We May Be Too Late (NASDAQ:VERA) - Seeking Alpha
Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Sells $753,725.00 in Stock - MarketBeat
Vera Therapeutics Insider Sold Shares Worth $753,680, According to a Recent SEC Filing - Marketscreener.com
Wellington Management Group LLP Sells 92,568 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - MarketBeat
Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Sold by State Street Corp - MarketBeat
Lord Abbett & CO. LLC Increases Position in Vera Therapeutics, Inc. (NASDAQ:VERA) - MarketBeat
Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Certain Class A common stock of Vera Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 15-DEC-2024. - Marketscreener.com
Marshall Fordyce Sells 17,500 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) Stock - MarketBeat
Vera Therapeutics CEO sells shares worth over $821k By Investing.com - Investing.com Canada
Vera Therapeutics CEO sells shares worth over $821k - Investing.com
Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Purchased by Y Intercept Hong Kong Ltd - MarketBeat
VERAVera Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Vera Therapeutics Grants $8.5M in Stock Options, RSUs to Attract Key Talent - StockTitan
Pier Capital LLC Invests $4.57 Million in Vera Therapeutics, Inc. (NASDAQ:VERA) - MarketBeat
Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Purchased by Point72 Asset Management L.P. - MarketBeat
Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Bought by Charles Schwab Investment Management Inc. - MarketBeat
베라 테라 (VERA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):